Benmoxin
Chemical compound
- None
- In general: ℞ (Prescription only)
- N'-(1-phenylethyl)benzohydrazide
- 7654-03-7
N
- 71671
- 64728
Y
- XC9FY2SGBG
- ChEMBL1877495
N
- DTXSID0046220
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- O=C(NNC(c1ccccc1)C)c2ccccc2
InChI
- InChI=1S/C15H16N2O/c1-12(13-8-4-2-5-9-13)16-17-15(18)14-10-6-3-7-11-14/h2-12,16H,1H3,(H,17,18)
Y
- Key:BEWNZPMDJIGBED-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Benmoxin (trade names Neuralex, Nerusil), also known as mebamoxine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class.[1][2] It was synthesized in 1967 and was subsequently used as an antidepressant in Europe, but is now no longer marketed.[1][2]
See also
- Hydrazine (antidepressant)
References
- ^ a b Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Vol. 1–2. Chapman & Hall. p. 229. ISBN 0-9630096-0-5.
- ^ a b Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
- v
- t
- e
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e